Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

[1] Hart RG(1999)Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 492-501

[2] Benavente O(2008)Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 133 160-98

[3] McBride R(2013)Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients Europace 15 486-93

[4] Pearce LA(2011)Atrial fibrillation: the cost of illness in Sweden Eur J Health Econ 12 479-87

[5] Ansell J(2003)Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 1019-26

[6] Hirsh J(2008)Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2029-37

[7] Hylek E(1993)A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 236-9

[8] Jacobson A(2008)Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 84-91

[9] Crowther M(2006)Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 1155-66

[10] Palareti G(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-51

[1] Hart RG(1999)Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 492-501

[2] Benavente O(2008)Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 133 160-98

[3] McBride R(2013)Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients Europace 15 486-93

[4] Pearce LA(2011)Atrial fibrillation: the cost of illness in Sweden Eur J Health Econ 12 479-87

[5] Ansell J(2003)Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 1019-26

[6] Hirsh J(2008)Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2029-37

[7] Hylek E(1993)A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 236-9

[8] Jacobson A(2008)Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 84-91

[9] Crowther M(2006)Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 1155-66

[10] Palareti G(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-51